RxDoctor Payments Data

Monica Corzo Pedrosa, MD

Infectious Disease · Bradenton, FLNPI 1649683566

Payments from drug & device makers

$1,583in general payments, 2019–2025

Across 73 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$285
  • AbbVie$255
  • Insmed, Inc.$244
  • Paratek Pharmaceuticals, Inc.$220
  • Melinta Therapeutics, LLC$212
  • Viiv Healthcare Company$144
  • plus $222 from 3 others

What the payments were for

  • Food & beverage$1,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,583 in reported general payments places this provider in the 60th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$240,457
Medicare patients
561
Services billed
70,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala115$450,650
DovatoDolutegravir Sodium/Lamivudine23$67,119
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$56,589
DescovyEmtricitabine/Tenofov Alafenam18$37,704
TivicayDolutegravir Sodium17$36,525
Daptomycin13$36,218
Doxycycline Hyclate59$1,719
CeftriaxoneCeftriaxone Sodium20$1,227
Entecavir11$1,000
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$318
Cefdinir14$305
Azithromycin11$261
Rifampin16$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$285$488,354133 claims
Viiv Healthcare CompanyDovato, Tivicay$144$103,64440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →